CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 52 enrolled
Drug / intervention
Albumin infusion, 2g/L of ascitic fluid aspiration.drug
Likely dose
Albumin infusion, 2g/L of ascitic fluid aspiration.from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06892535
NCT06892535Phase 4Completed

Low-Dose Albumin Infusion for the Prevention of Paracentesis Induced Circulatory Dysfunction (PICD), After Large Volume Paracentesis in Decompensated Cirrhosis of Liver.

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh·interventional·Posted Mar 24, 2025·Updated Mar 24, 2025

In Brief

A Phase 4 clinical trial evaluating Albumin infusion, 2g/L of ascitic fluid aspiration. for Paracentesis-Induced Circulatory Dysfunction. Completed, enrolled 52 participants across 1 site.

Detailed Summary

Abstract for thesis protocol. Background: Paracentesis induced circulatory dysfunction (PICD) is a common complication of large volume paracentesis in cirrhotic patients, which can lead to renal impairment, hyponatremia, and increased mortality. Albumin infusion is recommended to prevent PICD, but the optimal dose is unclear. We aim to compare the efficacy of low dose albumin infusion versus standard dose of albumin in preventing PICD in cirrhotic patients. Material and methods: We will conduct a randomized controlled trial with two arms: low dose albumin infusion (2g per liter of ascitic fluid removed) versus standard dose albumin infusion (6g per liter of ascitic fluid removed). Patients with liver cirrhosis undergoing large volume paracentesis (\>5 L) with serum creatinine \<1.5 mg/dL and no signs of infection will be included in the study. Sample size calculation: Based on previous studies, group sample size will be 26 and will achieve 80.749% power to reject null hypothesis. As per availability, 30 participants will be included in each group, with a total number of 60 for this trial. Outcome of the study: The primary outcome is the incidence of paracentesis induced circulatory dysfunction (PICD) in both groups, (Low dose albumin and standard dose of albumin), 7 days after paracentesis. The secondary outcomes are renal failure, hyponatremia, hepatic encephalopathy, hepatorenal syndrome, and length of hospital stay. Conclusion: This trial will provide evidence on whether low dose albumin infusion is as effective as standard dose albumin infusion in preventing PICD in cirrhotic patients. This could have implications for reducing the cost and optimal effective dose of albumin therapy, as well as improving the outcomes of patients with ascites.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBangladesh
Collaborators--

Timeline

Phase 4CompletedFinished
202420252026
First PostedMar 24, 2025
Enrollment StartFeb 2, 2024
Primary CompletionFeb 28, 2025
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 1.3 years ago

Interventions

Albumin infusion, 2g/L of ascitic fluid aspiration.drug

Albumin infusion lower than the standard dose, either 2g/L or 4g/L of ascitic fluid aspiration is termed as low dose.